Show simple item record

dc.contributor.authorTietz, O
dc.contributor.authorKamaly, N
dc.contributor.authorSmith, G
dc.contributor.authorShamsaei, E
dc.contributor.authorBhakoo, KK
dc.contributor.authorLong, NJ
dc.contributor.authorAboagye, EO
dc.date.accessioned2022-03-29T10:58:35Z
dc.date.available2022-03-29T10:58:35Z
dc.date.issued2013-01-01
dc.identifier.citationAmerican journal of nuclear medicine and molecular imaging, 2013, 3 (4), pp. 372 - 383
dc.identifier.issn2160-8407
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5053
dc.identifier.eissn2160-8407
dc.identifier.eissn2160-8407
dc.description.abstractThe G-protein coupled C-X-C chemokine receptor type 4 (CXCR4) is highly overexpressed in a range of cancers and is therefore an excellent biomarker for cancer imaging. To this end targeted iron oxide nanoparticles were developed and utilised for in vitro imaging of MDA-MB-231 breast cancer cells overexpressing the CXCR4 receptor. Nanoparticles comprising an iron oxide core, encapsulated in a stabilising epichlorohydrin crossed-linked dextran polymer, were conjugated to a cyclopentapeptide with affinity to the CXCR4 receptor. The particles were characterized for their size, surface charge and r2 relaxivity at 4.7 T. MR imaging of the CXCR4 receptor with targeted iron oxide nanoparticles revealed an approximately 3-fold increase in T2 signal enhancement of MDA-MB-231 cells compared to non-targeted controls. Prussian blue staining of labeled MDA-MB-231 cells revealed darker and more intense staining of the cellular membrane. This study demonstrates the potential of targeted iron oxide nanoparticles for the imaging of the CXCR4 receptor by magnetic resonance imaging (MRI).
dc.formatElectronic-Print
dc.format.extent372 - 383
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleDesign, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.
dc.typeJournal Article
dcterms.dateAccepted2013-06-21
rioxxterms.versionVoR
dc.relation.isPartOfAmerican journal of nuclear medicine and molecular imaging
pubs.issue4
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Biology of Childhood Leukaemia
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/21/22 Starting Cohort
pubs.publication-statusPublished
pubs.volume3
pubs.embargo.termsNo embargo
icr.researchteamPET Radiochemistry
icr.researchteamBiology of Childhood Leukaemia
dc.contributor.icrauthorSmith, Graham
dc.contributor.icrauthorShamsaei, Elham


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0